Onlikang issued a change announcement. The company is currently developing only 1 innovative drug project, the ALK-N001 project. As of the disclosure date of this announcement, the project is still in phase I clinical trials. On August 26, 2025, the company signed the “Strategic Cooperation Agreement License Agreement” with Yafei Biomedical Technology Co., Ltd. and Shanghai Qinheli Biomedical Technology Co., Ltd. for the ALK-N002 project. As of the disclosure date of this announcement, the matter has been reviewed and approved by the company's shareholders' meeting, and Yafei Biotech and Affinity are still undergoing internal approval procedures. The company specifically reminds investors to make rational decisions and pay attention to investment risks.

Zhitongcaijing · 10/19/2025 07:57
Onlikang issued a change announcement. The company is currently developing only 1 innovative drug project, the ALK-N001 project. As of the disclosure date of this announcement, the project is still in phase I clinical trials. On August 26, 2025, the company signed the “Strategic Cooperation Agreement License Agreement” with Yafei Biomedical Technology Co., Ltd. and Shanghai Qinheli Biomedical Technology Co., Ltd. for the ALK-N002 project. As of the disclosure date of this announcement, the matter has been reviewed and approved by the company's shareholders' meeting, and Yafei Biotech and Affinity are still undergoing internal approval procedures. The company specifically reminds investors to make rational decisions and pay attention to investment risks.